Deep Brain Provides Stimulating Market
There are signs that the field of deep brain stimulation (DBS) has gained a certain momentum of late: three start-ups raised venture rounds in 2011 and there have been two acquisitions in the space within the past year. DBS enables the giants in cardiac rhythm management – Medtronic, St. Jude Medical, and Boston Scientific –to leverage existing technology platforms from CRM to address a new area once served primarily by drugs, and start-ups can help them by validating new disease targets and increasing procedural accuracy and efficiency. The space is appealing because with a single platform, companies can address several diseases with large populations, such as depression and Alzheimer’s disease. But the opportunities remain far from certain with this highly complex technology.
You may also be interested in...
At its October Medical Innovation Summit, the Cleveland Clinic unveiled six device and diagnostics products that were selected for inclusion in its list of top 10 innovations for 2014.
Deep brain stimulation (DBS) currently comprises only about a quarter of the worldwide neuromodulation device market, but growth in this segment is strong. Both large and small competitors have targeted DBS, which has the potential to address a number of highly prevalent and underserved diseases and disorders.
A new company created by NDI Medical has a novel deep-brain stimulation algorithm for treating Parkinson’s disease, which, according to the firm, requires less power and may be more effective than currently available DBS systems for Parkinson’s.